Point-of-Care Metagenomics for Rapid Detection of pathogens and Antimicrobial Resistance in Sight-Threatening Ocular Infections
- Institution
- Massachusetts Eye and Ear Infirmary, MA
- Principal investigator
- Paulo J. M. Bispo
- Funding
- $361K
- Duration
- 2024–2029
Moonbase score
Still being scored
Abstract
PROJECT SUMMARY Timely and accurate diagnosis of ocular infections is critical to guide early effective therapy and save vision. However, because current methods for diagnosis of ocular infections are time-consuming and not sensitive, empirical treatment with broad-spectrum therapies selected on the basis of clinical judgment continues to be the mainstream approach. Since ocular infections are caused by a wide range of organisms, which may present with overlapping features, many patients are treated unnecessarily with inappropriate antimicrobials. These broad- spectrum scattershot approaches lead to increased toxicity, select for resistant bacteria, and are increasingly compromised by the global emergence of antimicrobial resistance (AMR). AMR is a global pandemic that poses a major threat to vision health, as ocular pathogens are becoming increasingly resistant to first-line antimicrobials used in ophthalmology. Unlike infections at many other sites, delays in diagnosis and in initiation of targeted effective treatment of ocular infections can lead to serious consequences. Treatment failures or reduced efficacy due to AMR can result in delayed infection resolution and consequences ranging from incremental visual loss to loss of the eye. Metagenomic sequencing-based approaches are increasingly being explored to detect pathogens and predict their antimicrobial resistances. Recent technological advancements now place the development of rapid near point-of-care diagnostic tests that employ third-generation sequencers (e.g., Oxford Nanopore) within reach. Our goal is to capitalize on these advances, and combine them with novel bioinformatic tools for real time pathogen identification and methods for pathogen enrichment to create a completely cultureless precision diagnostic tool for improved diagnosis of sight-threatening ocular infections. First, we will develop and validate a practical metagenomic sequencing approach for rapid, sensitive and comprehensive detection of bacteria, fungi and acanthamoeba from ocular samples using the portable Nanopore sequencer. This will be accomplished using specimens derived from ex-vivo models of keratitis and endophthalmitis with known microbial loads. Clinical validation will be performed using our existing large biorepositories of clinical specimens collected from patients presenting with sight-threatening keratitis and endophthalmitis and additional samples to be collected prospectively. Additionally, we will also adopt and validate direct association approaches for antibiotic resistance prediction using the minimum of new sequence information necessary. At the conclusion, we will have developed a rapid and culture-independent precision diagnostic approach that would transform ocular infection diagnosis and treatment from an empirical one-size-fits-all approach to a precise and more effective one tailored to the patient’s needs. This has the potential to significantly advance clinical management and help improve the care of patients suffering from sight-threatening infections.
LOADING MOONBASE SCORE
Questions for Massachusetts Eye and Ear Infirmary
Answered by the team behind this research.
No questions yet. Sign in to ask the first one
Related grants
Same researchers, same institution, same topic, scored first.
- NIH · Massachusetts Eye and Ear InfirmaryNot yet scored
Rapid Diagnosis of Ocular Infections using a Sensitive and Highly Multiplexed Broad Pathogen Detection Assay
Paulo J. M. Bispo · $425K · 2024–2029
- NIH · Massachusetts Eye and Ear Infirmary65
Clinical Validation of DystoniaNet Deep Learning Platform for Diagnosis of Isolated Dystonia
Kristina Simonyan · $674K · 2022–2028
- NIH · Massachusetts Eye and Ear Infirmary48
Subproject 4: Role of Pumps in Resistance, Physiology, and Infection
David C Hooper · $472K · 2009–2026